Unicycive Therapeutics In... (UNCY)
NASDAQ: UNCY
· Real-Time Price · USD
4.71
0.08 (1.73%)
At close: Aug 15, 2025, 3:59 PM
4.72
0.32%
After-hours: Aug 15, 2025, 07:57 PM EDT
Unicycive Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | -271K | -271K | -271K | 404K | 675K | 1.63M | 1.63M | 951K | 951K | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 134K | 418K | 366K | 445K | 523K | 284K | 204K | 126K | 50K | 7K | 6K | 5K | 3K | 1K | n/a | n/a | n/a |
Gross Profit | n/a | -284K | -637K | -716K | -794K | 120K | 471K | 1.5M | 1.58M | 944K | 945K | -5K | -3K | -1K | n/a | n/a | n/a |
Operating Income | -30.9M | -32.12M | -29.17M | -28.86M | -25.78M | -20.77M | -19.79M | -19.4M | -18.72M | -18.05M | -15.48M | -14.64M | -11.78M | -8.98M | -6.94M | -2.85M | -2.41M |
Interest Income | 1.42M | 1.26M | 1.09M | 898K | 670K | 615K | 475K | 248K | 14K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -15.2M | -36.73M | -23M | -23.31M | -37M | -30.62M | -28.15M | -29.3M | -29.1M | -18.06M | -15.48M | -15.13M | -12.59M | -10.02M | -8.14M | -3.65M | -2.88M |
Net Income | -15.2M | -36.73M | -23M | -23.31M | -37M | -41.19M | -38.73M | -39.88M | -39.68M | -18.06M | -15.48M | -15.13M | -12.59M | -10.02M | -8.14M | -3.65M | -2.88M |
Selling & General & Admin | 15.53M | 11.82M | 9.84M | 9.2M | 8.73M | 8.47M | 7.95M | 7.09M | 6.81M | 6.57M | 6.47M | 5.71M | 4.22M | 2.9M | 1.84M | 1.22M | 1.09M |
Research & Development | 15.37M | 20.01M | 18.96M | 19.29M | 16.68M | 12.9M | 12.51M | 13.94M | 13.53M | 12.44M | 9.96M | 8.93M | 7.56M | 6.08M | 5.1M | 1.63M | 1.32M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 30.9M | 31.83M | 28.8M | 28.49M | 25.41M | 21.37M | 20.46M | 21.03M | 20.34M | 19M | 16.43M | 14.64M | 11.78M | 8.98M | 6.94M | 2.85M | 2.41M |
Interest Expense | 66K | 71K | 70K | 73K | 89K | 81K | 65K | 50K | 18K | 6K | 3K | 55K | 376K | 628K | 791K | 812K | 493K |
Selling & Marketing Expenses | n/a | -284K | -366K | -366K | -366K | -82K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 22.91M | 32.12M | 29.17M | 28.86M | 25.78M | 21.45M | 20.46M | 21.03M | 20.34M | 19M | 16.43M | 14.64M | 11.78M | 8.98M | 6.94M | 2.85M | 2.41M |
Income Tax Expense | n/a | n/a | n/a | -79K | -47K | 10.53M | 10.53M | 10.62M | 10.58M | 6K | 3K | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 116.82M | 66.99M | 8.89M | 3.79M | 15.23M | 3.48M | 3.26M | 1.52M | 1.52M | 1.52M | 1.51M | 1.5M | 1.5M | 1.42M | 1.42M | 1.4M | 1.42M |
Shares Outstanding (Diluted) | 123.83M | 66.99M | 8.89M | 9.41M | 15.23M | 3.48M | 3.26M | 1.52M | 1.52M | 1.52M | 1.51M | 1.5M | 1.5M | 1.42M | 1.42M | 1.4M | 1.42M |
EPS (Basic) | -0.05 | -0.6 | -0.79 | -0.87 | -1.2 | -2.25 | -2.38 | -2.62 | -2.61 | -1.2 | -1.04 | -1.04 | -0.88 | -0.71 | -0.58 | -0.29 | -0.25 |
EPS (Diluted) | -0.28 | -0.83 | -1.02 | -1.1 | -1.2 | -2.25 | -2.38 | -2.62 | -2.61 | -1.2 | -1.04 | -1.04 | -0.88 | -0.71 | -0.58 | -0.29 | -0.25 |
EBITDA | -40.72M | -53.39M | -39.72M | -39.99M | -36.32M | -30.18M | -27.8M | -29.12M | -29.03M | -18.05M | -15.47M | -14.63M | -11.78M | -8.24M | -6.21M | -1.5M | -1.05M |
EBIT | -15.71M | -36.66M | -22.93M | -23.17M | -36.84M | -30.46M | -28.01M | -29.25M | -29.08M | -18.05M | -15.48M | -15.07M | -12.21M | -9.39M | -7.35M | -2.83M | -2.39M |
Depreciation & Amortization | 144K | 428K | 376K | 332K | 523K | 284K | 204K | 126K | 50K | 7K | 6K | 4.72M | 5.5M | 6.23M | 6.94M | 2.85M | 2.41M |